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Background: The effects of fish oil supplements on lipid profile in dialysis patients are controversial. With
increasing interest in the potential health benefits of fish oil, it is important to explore its real effects.
Objective: We aimed to identify and quantify the effects of fish oil on triglyceride (TG), total cholesterol (TC),
high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) in dialysis patients.
Methods: PubMed, EMBASE and the Cochrane Central Register of Controlled Trials were searched for relevant trials
of fish oil and lipid profile in dialysis patients. We identified 209 potential studies and included 13 randomized
controlled trials. Eligible studies, determined by consensus using predefined criteria, were reviewed in accordance
with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and a meta-analysis
was performed.
Results: Compared with the control group, serum TG and TC levels in the fish oil group were reduced by 0.23 mmol/L
(95% CI, −0.31, −0.14, P <0.01) and 0.12 mmol/L (95% CI, −0.23, −0.01, P =0.03), respectively. HDL-C levels were
increased by 0.20 mmol/L (95% CI, 0.01, 0.40, P <0.01) attributable to fish oil. In contrast, fish oil did not influence
serum LDL-C levels. Subgroup analysis showed the effects of fish oil were stronger in subjects with higher baseline TG
levels, and the long-term intervention (>12w) demonstrated a tendency towards greater improvement of serum HDL-C
and LDL-C levels compared with short-term intervention (≤12 w). However, both of the changes were not statistically
significant in meta-regression analysis. There were no obvious difference in effects of different doses and components
of fish oil on lipid levels.
Conclusion: Fish oil supplements reduced serum TG and TC levels, and increased HDL-C levels, without affecting
LDL-C levels among dialysis patients. It should benefit patients at risk of cardiovascular diseases. Based on randomized
controlled trials, we suggested a daily supplement dose of fish oil for dialysis patients of >1 g, but a high dose might
not be necessary.
Keywords: Fish oil, Dialysis, Lipid, Meta-analysisIntroduction
Dialysis patients have an inordinate risk of cardiovascular
disease (CVD), which remains a major cause of morbidity
and mortality in this patient group [1,2]. Dyslipidemia
is an established independent risk factor for CVD. It is
well known that in patients with end-stage renal disease
(ESRD), changes in lipid metabolism occur, creating a* Correspondence: zhukov2012@hotmail.com
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unless otherwise stated.complex form of dyslipidemia [3], and the lipid abnormal-
ities persist or are aggravated during renal replacement
treatment [4,5], which may partly explain the high inci-
dence of CVD [6].
In the past few years, there has been a growing scientific
and public interest in the role of omega-3 fatty acids,
mainly obtained from fish and fish oil in CVD, idiopathic
IgA nephropathy, lupus nephritis and renal failure. By
modulating cell membrane structure and function as well
as synthesis of lipid mediators such as eicosanoids, omega-. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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benefits to dialysis patients [7].
Numerous clinical trials concerning the effects of fish
oil supplements on serum lipids in dialysis patients have
been published. However, the results are still inconclusive,
because the trials included small numbers of patients and
different doses of fish oil, with short duration of obser-
vation. Therefore, we present the results of a systematic
review summarizing current evidence from randomized
controlled trials of the effects of fish oil supplements on
serum lipid profile in dialysis patients.
Methods
Search strategy
The systematic review was conducted in accordance
with PRSIMA guidelines [8]. The search used key words
related to dialysis (kidney failure, chronic renal failure,
dialysis, hemodialysis, peritoneal dialysis), omega-3 fatty
acids (fatty acid, omega-3, fish oil, α-linolenic acid, eicosa-
pentaenoic acid, docosahexanoic acid) and lipid (lipid,
cholesterol, triglyceride, lipoprotein, hyperlipidemia)
to identify randomized controlled trials published in the
English language covering the period from as early as pos-
sible to October 2013, from different computerized data-
bases including PubMed, EMBASE and the Cochrane
Central Register of Controlled Trials. In addition, the ref-
erence lists of the published papers on clinical trials, re-
view articles and meta-analysis were hand-searched for
other relevant studies. The investigators were contacted
for unreported lipid data in published trials. The titles and
abstracts of the articles were analyzed to ascertain con-
formity with the inclusion criteria. The full text of an art-
icle was reviewed carefully if the screening of its title and
abstract was unclear as to its admissibility. The complete
search strategy is available in the Additional file 1.
Selection criteria
We included published completed studies that enrolled
dialysis patients, regardless of the type of dialysis. Ran-
domized controlled trials were included if they met the
following criteria: (i) the study compared fish oil (any dose
or type) versus placebo/no treatment; (ii) concomitant
therapy with fish oil equally in both treatment arms; and
(iii) at least one of the following four outcomes were re-
ported: serum TG, TC, LDL-C, HDL-C. All the studies
were reviewed by two independent reviewers (Han Du, He
Zhang) and any disagreement was resolved by discussion.
Quality assessment
To comply with the Cochrane Handbook for Systematic
Reviews of Interventions in terms of quality assessment
of the randomized controlled trials, we evaluated the
quality of the studies in terms of allocation concealment
and intention-to-treat analysis, blinding of investigators,participants and outcome assessors, and completeness to
follow-up, as well as the Jadad scale [9-11]. The Jadad
scale was performed by two reviewers independently
(Wei Zhu, Jie Chen).
Data extraction
We followed a standard Cochrane protocol for study se-
lection and data extraction [12,13]. Study eligibility was
determined by consensus, based on previously deter-
mined inclusion criteria. Eligible studies were reviewed
independently by two authors (Wei Zhu, Feng Hu) who
used data extraction forms developed for this purpose.
We used consensus and a third reviewer (Chongya Dong),
if necessary, to resolve disagreements. Data were extracted
from all included trials in terms of baseline characteristics
of the trials, type of dialysis, the components and dose of
fish oil, follow-up duration, and the following reported
outcomes: serum TG, TC, LDL-C, and HDL-C. If an out-
come was reported at more than one time point in a single
study, the longest period of follow-up was used.
Data synthesis and statistical analysis
The mean difference in TG, TC, HDL-C and LDL-C
from baseline was extracted into meta-analysis as a con-
tinuous variable. The effects of fish oil compared with
control oil on the lipid profile were defined as the mean
difference between the changes in serum lipid concen-
tration. The mean changes were calculated by subtract-
ing the baseline values from the final values. For studies
only reporting data of the pre-intervention mean and SD
and the post-intervention mean and SD, we inputted the
missing SD of changes from baseline using a correlation
coefficient of 0.7, as calculated and averaged based on
studies with complete outcome reports [14-17]. For
cross-over studies, the correlation coefficient was 0.797,
as calculated based on a complete outcome report with
cross-over design [18].
Heterogeneity among studies was assessed using
Cochran’s Q test and I2 statistic. P <0.05 or I2 > 50% was
considered significant. In that case, the random effects
model was used as the pooling method. Otherwise, the
fixed effect model was chosen. Funnel plots and Egger’s
regression were used to assess the potential publication
bias.
We excluded the study by Taziki after the data synthe-
sis phase [19], and the correlation coefficient was not
available in primary reports, therefore we performed a
sensitivity analysis.
The components and dose of fish oil, duration of
intervention, and initial lipid levels may influence the re-
sults, therefore we performed subgroup comparisons
based on the parameters above. Because these previous
studies measured fish oil as a whole and it has been re-
ported that DHA and EPA content varied in different
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basis of the dose of DHA + EPA in the included trials.
Meta-regression was performed to compare the effects
of these subgroup characteristics on the outcomes.
Review Manager 5.2 created by the Cochrane Collab-
oration for meta-analysis (http://www.cochrane.org) was
used for statistical analysis.
Role of the funding source
This study had no funding source. The corresponding
author had full access to all the data in the study and




A total of 209 articles were found in our initial search,
and 178 were excluded by screening the titles or ab-
stracts, because they were animal studies, basic research
studies, review articles, or non-randomized controlled
trials, and they did not enroll dialysis patients or com-
pare fish oil versus placebo/no treatment. Full-text as-
sessment of the 31 potentially relevant articles resulted
in 13 eligible randomized controlled studies. The reasons
for exclusion were as follows: one article was a review
one trial was not randomized and controlled trial, one
full-text was a study protocol, and 13 studies did not
report sufficient lipid detail for inclusion in the meta-
analysis. Two studies had the same first author, dialysis
clinics, start and end point, inclusion and exclusion cri-
teria [20,21], and we confirmed that 33 patients had been
included in both studies. In the absence of prompt avail-
ability of patient-level data for both trials, we only in-
cluded the trial with the highest number of patients [20].
One trial was excluded because we found the data quality
questionable. Unfortunately, we were unable to contact
the author to confirm the data quality. Finally, all the au-
thors agreed to exclude it after discussion. The reasons
were as follows: (i) Fasting serum TC should be >220 mg/
dl as per the inclusion criteria. However, the baseline
levels provided for both groups (102 ± 32 and 229 ±
31 mg/dl) were not within the inclusion criteria [22]; (ii)
The baseline TG level in the drug group was significantly
higher than in the control group (321 ± 29 vs 268 ±
22 mg/dl), and the baseline TC level was significantly
lower (102 ± 32 vs 229 ± 31 mg/dl). Both groups should
have matching data. This could be the cause of the appar-
ent benefit with fatty acid supplementation. The data
regarding baseline TG of the control group in the
two tables are different (268 ± 22 and 268 ± 32 mg/dl)
[22]. We included the study by Poullia in spite of pa-
tients received different α-tocopherol doses as concomi-
tant therapy [18], because the supplement aimed to control
the possible effects of α-tocopherol present in Omacorcapsules, and had no impact on lipid profile [23]. A flow
diagram of the article selection for this meta-analysis is
shown in Figure 1.
Quality assessment
Quality assessment of the primary studies is summarized
in Table 1. The Jadad scores ranged from 0 to 5 points.
Study quality on the whole was good; five of 13 studies
had a Jadad score of 5, four of 13 had a Jadad score of 3
or 4, and four of 13 had a Jadad score of ≤2. Participants
and investigators were blinded in nine of 13 trials; suffi-
cient details of drop-outs and withdrawals were de-
scribed in 13 trials, two studies complied with allocation
concealment; and 4 studies met the intention-to-treat
analysis criteria.
Study characteristics
We identified 13 trials with 764 subjects in our study
[14-18,20,24-30]. The characteristics of the trials are
shown in Table 2. One study focused on hyperlipidemia
patients. One study enrolled subjects with serum albu-
min ≤3.9 g/dl. Eleven of the trials were parallel trials and
two were cross-over studies. Ten of the trials enrolled
patients on hemodialysis, one trial on peritoneal dialysis,
and two on both peritoneal dialysis and hemodialysis.
Duration of fish oil supplementation was 4 weeks to
12 months. The daily amount of EPA + DHA supple-
ment ranged from 0.9 g (dose of EPA +DHA was esti-
mated as 60% of fish oil dose) to 3 g [16,19]. All 13
studies reported the effects on TG levels; 12 studies re-
ported the effects on cholesterol, and nine and eight
studies investigated the effects of fish oil on HDL-C and
LDL-C, respectively.
Effects of fish oil supplementation on lipid concentrations
The effects of fish oil on the levels of TG, TC, HDL-C
and LDL-C in all studies are shown in Figures 2, 3, 4
and 5, respectively. Overall, the pooled analysis of the
effects of fish oil intake on TG levels showed a decrease
of 0.23 mmol/L compared with the control group (95%
CI, −0.31, −0.14, P <0.01) (Figure 2). Fish oil also sig-
nificantly lowered serum TC levels by 0.12 mmol/L
(95% CI, −0.23, −0.01, P =0.03) (Figure 3). Fish oil
significantly increased HDL-C levels by 0.20 mmol/L
(95% CI, 0.01, 0.40, P <0.01). Heterogeneity was observed
for the HDL-C outcome (heterogeneity chi-square =
836.86, I2 = 97%, P = 0.04) (Figure 4). Fish oil did not
have any significant influence on LDL-C (mean differ-
ence −0.03 mmol/L; 95% CI, −0.15, 0.09, P = 0.62) (Figure 5).
Publication bias
The potential publication bias was detected by funnel
plots and Egger’s regression test (Figure 6). The results
suggested no publication bias for the effects of fish oil
Searched relevant articles(n=209) 
178 publications excluded





Non-randomized controlled trials 
Potential relevant references for further full text 
screened(n=31)
16 publications excluded
Review articles (n =1)
Non-randomized controlled trials (n =1)
Study protocol(n=1) 
Insufficient lipid information(n=13)    
Articles meeting inclusion criteria(n=15) 
2 publications excluded
33 patients common to 2 trials(n=1) 
data considered doubtful(n=1) 
Include 13 articles
TG (n=12) TC(n=12) HDL-C (n=9) LDL-C (n=8)  
Figure 1 Flow diagram of study selection process.
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ever, funnel plots revealed that publication bias existed
for HDL-C, which was also illustrated by Egger’s regres-
sion test (P <0.01). It may have been caused by two arti-
cles whose results deviated from the others [20,27], and
negative results about HDL-C are published less often.
Subgroup analyses
The results of the subgroup analyses are shown in Table 3.








Diskin, 1990 [24] 1 0 0
Donnelly, 1992 [25] 1 0 1
Ando, 1999 [26] 1 0 0
Khajehdehi, 2000 [27] 1 0 0
Schmitz, 2002 [28] 1 1 1
Saifullah, 2007 [14] 1 1 1
Svensson 2008 [29] 1 1 1
Bowden, 2009 [20] 1 1 1
Poulia, 2011 [18] 1 0 0
Kooshki, 2011 [15] 1 1 1
W.S. An, 2011 [30] 1 1 1
Lok, 2012 [16] 1 1 1
Daud, 2012 [17] 1 0 1greater in patients with higher baseline TG levels. The
mean change in TG in the subgroups with baseline
levels ≥2.26, 1.69-2.26 and ≤1.69 mmol/L was −0.56, −0.18
and −0.24 mmol/L, respectively. However, no significance
could be found in meta-regression analysis (P =0.75).
Long-term (>12 w) intervention demonstrated a tendency
towards greater improvement in serum HDL-C and LDL-C
levels compared with short-term intervention (≤12 w). The
mean change in HDL-C in the ≤12 w and >12 w subgroups















0 1 2 3/7 no unknown
1 1 4 3/16 yes unknown
0 1 2 0/38 no unknown
0 1 2 0/60 no unknown
1 1 5 1/24 yes unknown
1 1 5 4/27 no unknown
1 1 5 54/206 no adequate
1 1 5 9/96 yes unknown
0 1 2 8/30 no unknown
0 0 3 0/34 no unknown
0 1 4 4/18 no unknown
1 1 5 5/201 yes adequate
1 1 4 9/63 yes unknown
Table 2 Characteristics of randomized, controlled trials included in the meta-analysis
Reference Additional
information
Population Sex(M + F) Age HD + PD Duration Treatment group Control group
F/C F/C F/C(SD or SE) F/C
Diskin, 1990 [24] Unspecified 4/3 NA NA 4 + 0/3 + 0 24 w EPA (3 g/d) placebo
Donnelly, 1992 [25] 1DM 14/15 5 + 3/7 + 1 52 (14)/51 (12) 4 + 4/4 + 4 4 w fish oil (3.6 g/d) (12%DHA/18%EPA) olive oil
Ando, 1999 [26] HD:16DM/22,
PD:0DM/16
19/19 17 + 2/16 + 3 54 (11)/51 (13) 11 + 8/11 + 8 3 m EPA (1.8 g/d) placebo
Khajehdehi, 2000 [27] DM 15% 15/15 8 + 7/7 + 8 32.7 (10.7)/31.1 (8.8) 15 + 0/15 + 0 2 m fish oil (1.5 g/d) corn oil (4.5 g/d), seasame
oil (4.5 g/d), placebo
Schmitz, 2002 [28] Unspecified 12/12 5 + 7/6 + 6 52 (6)/54 (3) 12 + 0/12 + 0 3 m fish oil (4 g/d)(24%DHA/44%EPA) corn oil(4 g/d)
Saifullah, 2007 [14] Unspecified 15/8 11 + 4/7 + 1 58 (12)/57 (14) 15 + 0/8 + 0 12 w fish oil (DHA 170 mg/d × 2, EPA 340 mg/d × 2) placebo (soybean/corn
oil mixture)
Svensson 2008 [29] Unspecified 35/38 NA NA 35 + 0/38 + 0 3 m omega-3 PUFA (1.7 g/d) (45%EPA/37.5%DHA) olive oil
Bowden, 2009 [20] Unspecified 44/43 25 + 19/20 + 23 59.3 (12.7)/60.8 (10.3) 44 + 0/43 + 0 6 m fish oil (6 g/d) (EPA 0.96 g/d, DHA 0.6 g/d) corn oil (6 g/d)
Poulia, 2011 [18] Unspecified 22/23 NA NA 22 + 0/23 + 0 4 w omega-3 (EPA 920 mg/d, DHA 760 mg/d) +
VitE 8 mg/d
VitE (14.2 mg/d)




W.S. An, 2011 [30] Unspecified 7/7 4 + 3/3 + 4 51.6 (8.7)/52.6 (12.1) 0 + 7/0 + 7 12 w fish oil (3 g/d)EPA 460 mg/d × 3 + 380 mg
DHA/d × 3
corn oil
Lok, 2012 [16] Unspecified 99/97 NA NA 99 + 0/97 + 0 6 m,12 m fish oil (4 g/d) (EPA 1600 mg/d, DHA 800 mg/d) olive oil (3 g/d)
Daud, 2012 [17] ALB < 3.9 g/dl 31/32 20 + 11/20 + 12 59 (13)/58 (12) 31 + 0/32 + 0 24 w protein + omega-3 (2.4 g) (EPA 1800 mg,
DHA 600 mg), three times a week
protein + olive oil, three
times a week





































Heterogeneity: Chi² = 16.99, df = 12 (P = 0.15); I² = 29%














































































Mean Difference Mean Difference
IV, Fixed, 95% CI
-4 -2 0 2 4
Favours experimental Favours control
Figure 2 Forest plots depicting the effect of fish oil supplement on TG. IV, inverse variance; fixed, fixed effects model; CI, confidence interval.
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and −0.12 mmol/L, respectively. However, meta-regression
analysis showed no significant association between serum
HDL-C or LDL-C outcomes and duration of intervention
(P =0.12, P =0.31). There was no significant difference in
the effects between doses and components of fish oil on
lipid levels.
Sensitivity analysis
For sensitivity analysis, because we used a correlation co-
efficient of 0.7 to input the missing SD of changes from
baseline as calculated and averaged based on studies with
complete outcome reports, we also inputted correlation
















Heterogeneity: Chi² = 16.49, df = 12 (P = 0.17); I² = 27%















































Figure 3 Forest plots depicting the effect of fish oil supplement on Tsignificance of the pooled changes in TG, TC, LDL-C and
HDL-C.
Although the trial by Taziki was excluded [19], we also
analyzed the results that included Taziki’s trial data.
We compared the results when we included and ex-
cluded Taziki’s trial data. The significance of the pooled
changes in TG, TC, LDL-C and HDL-C was not altered,
except that including the Taziki data changed the homo-
geneity of the TG and TC studies (I2: TG 29 to 73%, TC
27 to 72%).
The results of two studies deviated from others obvi-
ously, which may be the reason for the positive publica-
tion bias result for HDL-C [20,27]. Therefore, we analyzed
















Mean Difference Mean Difference
IV, Fixed, 95% CI
-4 -2 0 2 4
Favours [experimental] Favours [control]
C. IV, inverse variance; fixed, fixed effects model; CI, confidence interval.
Figure 4 Forest plots depicting the effect of fish oil supplement on HDL-C. IV, inverse variance; fixed, fixed effects model; CI, confidence interval.
Zhu et al. Lipids in Health and Disease 2014, 13:127 Page 7 of 11
http://www.lipidworld.com/content/13/1/127same conclusion as before. Fish oil did not have any signifi-
cant influence on HDL-C (mean difference −0.01 mmol/L;
95% CI, −0.03, 0.02 mmol/L, P =0.90).
Discussion
Our meta-analysis showed supplementation with fish oil
was associated with a decrease in TG and TC, and an
increase in HDL-C, but had no significant effects on
LDL-C compared with controls. Funnel plots and Egger’s
regression test showed possible publication bias for HDL-C,
but not for other parameters.
The results of the current meta-analysis on TC, TG,
LDL-C and HDL-C were similar to those of Pei [32], in
which fish oil was found to reduce serum TG levels signifi-
cantly by −0.78 mmol/L (95% CI: −1.12, −0.44 mmol/L,
P <0.01), but had no significant effect on TC, HDL-C
and LDL-C compared with controls. However, there were
several differences between the two studies. The two stud-
ies by Svensson and Bouzidi [33,34] were included in
the study of Pei, but were excluded in the current study,Figure 5 Forest plots depicting the effect of fish oil supplement on LDLbecause the patients enrolled in the two studies did not
undergo dialysis treatment. We were able to confirm that
two studies of Bowden were based on the same population
[20,21], so we excluded the smaller sample study [21]. The
trial by Taziki was excluded in our meta-analysis [19], but
included in the analysis of Pei. We also added seven stud-
ies not included in Pei’s review because of small sam-
ple sizes (<15 patients in either arm) and search dates
[15-18,24,29,30]. Furthermore, we added several sub-
group analyses based on components of fish oil and initial
lipid levels.
Subgroup analyses revealed good long-term trends in
the effects of supplements of fish oil on serum HDL-C
and LDL-C levels. However, as mentioned before, the de-
gree of improvement did not achieve statistical signifi-
cance, which may have been due to a lack of statistical
power. If we want to clarify the long-term effect, more
specific studies should be conducted.
There are two issues that need to be carefully scruti-
nized. The first is that the optimal daily dose in dialysis-C. IV, inverse variance; fixed, fixed effects model; CI, confidence interval.
Funnel plot with pseudo 95% confidence limits
Change in mean TG 
Funnel plot with pseudo 95% confidence limits
Change in mean TC 
Funnel plot with pseudo 95% confidence limits Funnel plot with pseudo 95% confidence limits
Change in mean HDL-C Change in mean LDL-C 
Figure 6 Funnel plots of studies included in meta-analysis on the effects of fish oil on serum lipid parameters. The results show
potential publication bias for HDL-C, but not for other parameters.
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lished. In our study, the content of fish oil supplements
varied significantly. It is impossible to determine the
precise content of each supplement, thus the dose of
DHA and EPA varied, so we used the dose of EPA +
DHA for subgroup analysis. We found no difference in
the effects on lipid profile when comparing <2 g EPA +
DHA supplement with ≥2 g, therefore a high dose of fish
oil supplement for lowering lipid levels might not be
needed. As a result of dietary restrictions on fish con-
sumption, to control phosphorus intake, dialysis patients
have significantly lower levels of omega-3 fatty acids
in their erythrocyte membranes [35], and based on ran-
domized controlled trials, we suggest that the daily
supplement dose of fish oil for dialysis patients should
be >1 g. This is different from the current recommended
dose of up to 1 g/day, by the American Heart Association
(AHA) and various international health organizations [36,37].Second, the truly active component of fish oil account-
ing for the lipid-altering effects is still unclear. After a
period of DHA supplementation, Harrison reported no
significant changes in LDL-C or TC, and a concomitant
increase in HDL-C. The authors further speculated that
only EPA has lipid-modulating effects [38]. We tried to es-
tablish whether EPA and DHA had a different impact on
lipid profile through subgroup analyses. Our study con-
firmed that EPA had a significant influence on lipid pro-
file, and EPA +DHA showed the same lipid-modulating
effects as EPA alone. Unfortunately, we could not draw
any conclusion about the effect of DHA alone on lipid
profile in dialysis patients.
The lipid-altering effects of fish oil may be attributed to
many factors [7]. Cell membrane fatty acids play an im-
portant role in signal transduction, therefore omega-3
fatty acids are capable of modifying gene expression. It is
believed that the dramatic lipid-altering effects of omega-
Table 3 Result of subgroup analyses
Subgroup TG TC HDL-C LDL-C
Effect size 95% CI I2(%) Effect size 95% CI I2(%) Effect size 95% CI I2(%) Effect size 95% CI I2(%)
Baseline TG (mmol/L) ≥2.26 −0.56 −0.95, −0.17 66 −0.06 −0.36, 0.23 78 0.33 −0.07, 0.74 97 −0.11 −0.73, 0.51 -
1.69-2.26 −0.18 −0.30, −0.05 0 −0.15 −0.30, −0.01 20 0.32 −0.27, 0.91 99 −0.08 −0.23, 0.07 76
≤1.69 −0.24 −0.36, −0.12 0 −0.08 −0.29, 0.13 0 0.01 −0.06, 0.08 0 7 −0.13, 0.26 0
Baseline TC (mmol/L) >5.17 −0.70 −1.24, −0.16 - 0.18 −0.15, 0.51 0 −0.02 −0.05, 0.01 - −0.03 −0.15, 0.09 45
≤5.17 −0.22 −0.30, −0.13 21 −0.16 −0.28, −0.04 21 0.23 −0.02, 0.48 97 - - -
Component of fish oil EPA −1.18 −1.99, −0.37 - −0.88 −1.62, 0.13 0 0.00 −0.13, 0.13 - - - -
EPA + DHA −0.22 −0.31, −0.14 0 −0.09 −0.21, 0.02 12 0.23 0.01, 0.44 97 - - -
Dose of EPA + DHA <2 g −0.24 −0.35, −0.13 45 −0.15 −0.28, −0.02 40 0.23 0.01, 0.45 97 −0.11 −0.26, 0.03 33
≥2 g −0.21 −0.34, −0.08 0 −0.06 −0.27, 0.15 0 −0.20 0.01, 0.40 - 0.14 −0.07, 0.34 46
Duration ≤12w −0.23 −0.32, −0.14 44 −0.11 −0.24, 0.02 37 0.12 −0.01, 0.26 90 0.06 −0.10, 0.23 0
>12w −0.24 −0.46, −0.01 0 −0.15 −0.38, 0.07 20 0.44 −0.37, 1.26 97 −0.12 −0.29, 0.04 82
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http://www.lipidworld.com/content/13/1/1273 fatty acids are mediated via this mechanism [39]. Spe-
cifically, omega-3 fatty acids modulate the function of
peroxisome proliferator-activated receptors and sterol
regulatory binding proteins, both of which are involved in
lipid homeostasis [40,41].
Although fish oil is generally well tolerated, attention
should be paid to the safety of fish oil supplementation
at doses >1 g/day. Most adverse effects involve a transi-
ent minimal decrease in the desire for food [27], gastro-
intestinal complaints (e.g. gas, bloating, fishy aftertaste
[28], nausea and burping [14]), and prolonged bleeding
time [25]. Serious bleeding complications were restricted
to a single patient in one study [24]. However, the ma-
jority of studies were not designed to measure side ef-
fects and tolerability after long-term use.
CVDs are the most important cause of mortality in pa-
tients undergoing hemodialysis. The frequency of CVD
in dialysis patients has been reported as 3–45 times that
observed in the general population and 50% of deaths in
these patients are related to CVD [42]. Lipid abnormalities
often complicate chronic renal failure and persist or are
aggravated during renal replacement treatment [4,43].
Large cohort studies have shown an inverse association
between cardiovascular morbidity and mortality and fish
oil ingestion [44,36]. Lok found that among patients with
new hemodialysis grafts, daily ingestion of fish oil im-
proved cardiovascular event-free survival [16]. Friedman
showed that long-chain omega-3 fatty acids are strongly
and independently associated with a lower risk of sudden
cardiac death in hemodialysis patients throughout the first
year of dialysis [45]. Except for lipid modulation, fish oil
may reduce cardiovascular events by several mechanisms,
including anti-inflammatory, antiarrhythmic and plaque-
stabilizing effects as well as improved endothelial effects
[46,47]. However the potential benefits of fish oil on car-
diovascular events deserve confirmation in future studies.
There were some strengths and limitations to our study.
We had more strict inclusion criteria, and analyzed almost
all the lipid parameters mentioned in the literature. A
series of important subgroup analyses were also per-
formed. However, the following limitations must be men-
tioned. First, none of the trials was sufficiently powered
because of the small numbers of participants. Second,
until now, there has been insufficient evidence for the ef-
fectiveness of long-term supplementation with fish oil on
lipid profile, because the longest duration in these trials
was only 48 weeks [12]. Third, publication bias is a major
potential limitation of meta-analysis that has been mini-
mized by contacting investigators for unpublished results.
Funnel plots and Egger’s regression test showed possible
publication bias for HDL-C, and sensitivity analysis found
that the significance of the change in HDL-C level was al-
tered. We must interpret the HDL result with caution. Fi-
nally, none of the studies were specifically designed toassess the effects of fish oil in dyslipidemia patients, thus
it was not accurate to evaluate the lipid-altering effects in
this group. Based on the above, the results derived from
this meta-analysis should be treated with considerable
caution.
Conclusions
This meta-analysis suggests that fish oil reduces serum
TG and TC levels, and increases HDL-C levels, without
influencing LDL-C levels among patients undergoing
dialysis treatment. This effect may directly account for
part of the observed benefits of fish intake on cardiovas-
cular risk. Based on randomized controlled trials, we
suggest that the daily supplement dose of fish oil for dia-
lysis patients should be >1 g, but a high dose might not
be necessary. Future large-scale randomized trials with
adequate doses and duration of treatment are needed to
determine the effect of fish oil supplements on lipid pro-
file in dialysis patients, especially those with CVD.
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